Transparency notification BlackRock, Inc.

Brussels (Belgium), 12 March 2025 – 20:00 (CEST) – Regulated information 

1.  Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it received a transparency notification from BlackRock, Inc. (having its registered office at 50 Hudson Yards, New York, NY, 10001, U.S.A.), on 11 March 2025. 

BlackRock, Inc. notified that, following an acquisition of UCB shares with voting rights by its affiliates, its shareholding in UCB SA increased and crossed the 5% threshold upwards on 10 March 2025. 

On 10 March 2025, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 725 971 UCB shares with voting rights and 126.101 assimilated financial instruments, representing together 5.07% of the total number of shares issued by the company (194 505 658), versus 5.10% (9 699 063 UCB shares and 215 582 assimilated financial instruments) in the previous notification dated 7 March 2025.

2.  Content of the notification

• Reason for the notification: Acquisition or disposal of voting securities or voting rights.
• Notification by: A parent undertaking or a controlling person.
• Persons subject to the notification requirement: 

• Date on which the threshold is crossed: 10 March 2025. 
• Threshold crossed (in %): 5%.
• Denominator: 194 505 658
• Notified details:

• Chain of controlled undertakings through which the holding is effectively held: Please see the full chain of control in the ‘Chain of Control’ tab.
• Additional information: The disclosure obligation arose due to voting rights attached to shares for BlackRock, Inc going above 5%

3.  Further information 

This press release and the detailed transparency notification are available on UCB SA/NV’s website via the following link.
An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link.

For further information, contact UCB: 

Investor Relations
Antje Witte 
T +32 2 559 94 14
antje.witte@ucb.com

Corporate Communications
Laurent Schots 
T+32 2 559 92 64
laurent.schots@ucb.com     

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of € 6.1 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news